Table 2.
≤2 cm | >2 cm | All | P (≤2 vs >2) | |
---|---|---|---|---|
n | 66 | 161 | 227 | |
Surgery | ||||
Whipple’sa | 31 (47%) | 52 (32%) | 83 (37%) | 0.015 |
Distal pancreatectomy | 30 (45%) | 103 (64%) | 133 (59%) | |
Enucleation | 5 (8%) | 3 (2%) | 8 (4%) | |
Other | 0 | 3 (2%) | 3 (1%) | |
Liver resection | 2 (3%) | 29 (18%) | 31 (14%) | 0.002** |
30-day mortality | 0 | 4 (2%) | 4 (2%) | 0.325 |
Margin | ||||
R0 | 53 (88%) | 115 (79%) | 168 (82%) | 0.549 |
R1 | 5 (8%) | 20 (14%) | 25 (12%) | |
R2 | 2 (3%) | 10 (7%) | 12 (6%) | |
Diameter | 14.7 (5) | 51.8 (33) | 40.4 (32) | <0.001*** |
Local invasion | 12 (18%) | 117 (73%) | 129 (57%) | <0.001*** |
Vascular invasion | 9 (14%) | 61 (38%) | 70 (31%) | <0.001*** |
Nodal metastasis | 13 (20%) | 70 (43%) | 83 (37%) | <0.001*** |
Lymph node ratiob | ||||
0 | 51 (77%) | 79 (49%) | 130 (57%) | 0.001** |
0–0.2 | 1 (2%) | 10 (6%) | 11 (5%) | |
>0.2 | 3 (5%) | 27 (17%) | 30 (13%) | |
ENETS stage | ||||
I | 39 (59%) | 0 | 39 (17%) | <0.001*** |
II | 6 (9%) | 57 (35%) | 63 (28%) | |
III | 11 (17%) | 43 (27%) | 54 (24%) | |
IV | 10 (15%) | 60 (37%) | 70 (31%) | |
Malignantc features | 25 (38%) | 140 (87%) | 165 (73%) | <0.001*** |
Ki67% | 4 (5) | 10 (17) | 8.01 (15) | 0.004** |
WHO 2010 grade | ||||
G1 ≤2% | 42 (64%) | 62 (39%) | 104 (46%) | 0.002** |
G2 3–20% | 20 (30%) | 67 (42%) | 87 (38%) | |
G3>20% | 2 (3%) | 24 (15%) | 26 (11%) | |
CgAd elevated | 4 (24%) | 26 (47%) | 30 (42%) | 0.122 |
Metachronous metastases | 1 (2%) | 18 (18%) | 19 (8%) | 0.01* |
aWhipple’s category includes pylorus-preserving pancreatoduodenectomies and duodenum preserving pancreatectomies; blymph node ratio = positive nodes/nodes sampled; cmalignant features are defined as local invasion, vascular invasion, lymph node metastasis or distant metastasis (synchronous or metachronous); dCgA = chromogranin A. *P < 0.05. **P < 0.005.